Xisha Chen

1.1k total citations · 1 hit paper
21 papers, 800 citations indexed

About

Xisha Chen is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Xisha Chen has authored 21 papers receiving a total of 800 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 7 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Xisha Chen's work include Autophagy in Disease and Therapy (6 papers), Ubiquitin and proteasome pathways (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Xisha Chen is often cited by papers focused on Autophagy in Disease and Therapy (6 papers), Ubiquitin and proteasome pathways (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Xisha Chen collaborates with scholars based in China, United States and Saudi Arabia. Xisha Chen's co-authors include Yan Cheng, Jinming Yang, Lanya Li, Yidi Guan, Xinluan Wang, Yan Cheng, Pian Yu, Min Tian, Xingcong Ren and Yi Zhang and has published in prestigious journals such as Cancer, Oncogene and Biochemical and Biophysical Research Communications.

In The Last Decade

Xisha Chen

18 papers receiving 792 citations

Hit Papers

DNA Repair Pathways in Cancer Therapy and Resistance 2021 2026 2022 2024 2021 50 100 150 200

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xisha Chen China 13 544 217 189 123 107 21 800
Yidan Ren China 14 622 1.1× 252 1.2× 307 1.6× 109 0.9× 108 1.0× 23 1.0k
Teng Yu China 18 496 0.9× 177 0.8× 139 0.7× 117 1.0× 107 1.0× 47 906
Yidi Guan China 12 525 1.0× 151 0.7× 196 1.0× 93 0.8× 33 0.3× 22 691
Kumiko Hongo Japan 13 366 0.7× 277 1.3× 192 1.0× 279 2.3× 65 0.6× 34 795
Elena Aréchaga-Ocampo Mexico 17 506 0.9× 148 0.7× 247 1.3× 63 0.5× 62 0.6× 35 747
Hongmei Yong China 18 601 1.1× 233 1.1× 273 1.4× 81 0.7× 146 1.4× 41 878
Can‐Can Zheng China 15 618 1.1× 217 1.0× 269 1.4× 62 0.5× 56 0.5× 22 888
Ji-Young Jang South Korea 14 596 1.1× 207 1.0× 322 1.7× 102 0.8× 166 1.6× 18 908
Virginie Poindessous France 17 484 0.9× 282 1.3× 187 1.0× 68 0.6× 65 0.6× 32 837
Tamer E. Fandy United States 18 874 1.6× 213 1.0× 103 0.5× 119 1.0× 91 0.9× 37 1.2k

Countries citing papers authored by Xisha Chen

Since Specialization
Citations

This map shows the geographic impact of Xisha Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xisha Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xisha Chen more than expected).

Fields of papers citing papers by Xisha Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xisha Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xisha Chen. The network helps show where Xisha Chen may publish in the future.

Co-authorship network of co-authors of Xisha Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Xisha Chen. A scholar is included among the top collaborators of Xisha Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xisha Chen. Xisha Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shu, Bing, et al.. (2025). Pleiotropic effects of SGLT2 inhibitors: A focus on macrophage-mediated action. Pharmacological Research. 222. 108046–108046.
2.
Zhang, Wenjie, Min Xia, Jiahui Li, et al.. (2025). Warburg effect and lactylation in cancer: mechanisms for chemoresistance. Molecular Medicine. 31(1). 146–146. 7 indexed citations
3.
Liang, Yuxin, Pei Li, Rongfang He, et al.. (2025). DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8+ T cell immunity in TNBC. Molecular Therapy. 34(2). 985–1008. 1 indexed citations
5.
Duan, Shan, et al.. (2024). Overexpression of COL11A1 confers tamoxifen resistance in breast cancer. npj Breast Cancer. 10(1). 38–38. 5 indexed citations
6.
Chen, Xisha, et al.. (2024). ZBTB7A as a therapeutic target for cancer. Biochemical and Biophysical Research Communications. 736. 150888–150888.
7.
Zhou, Xiaoming, et al.. (2023). The role of ubiquitin pathway‐mediated regulation of immune checkpoints in cancer immunotherapy. Cancer. 129(11). 1649–1661. 5 indexed citations
8.
Jiang, Shilong, Xisha Chen, Lanya Li, et al.. (2021). CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway. Chemico-Biological Interactions. 351. 109747–109747. 6 indexed citations
9.
Chen, Xisha, et al.. (2021). Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance. Drug Resistance Updates. 56. 100752–100752. 48 indexed citations
10.
Li, Lanya, Yidi Guan, Xisha Chen, Jinming Yang, & Yan Cheng. (2021). DNA Repair Pathways in Cancer Therapy and Resistance. Frontiers in Pharmacology. 11. 629266–629266. 248 indexed citations breakdown →
11.
Wang, Haiyan, Pian Yu, Xisha Chen, et al.. (2021). Identification of HMGCR as the anticancer target of physapubenolide against melanoma cells by in silico target prediction. Acta Pharmacologica Sinica. 43(6). 1594–1604. 18 indexed citations
12.
Li, Lanya, Xisha Chen, Kuan-Song Wang, et al.. (2020). RSK2 protects human breast cancer cells under endoplasmic reticulum stress through activating AMPKα2-mediated autophagy. Oncogene. 39(43). 6704–6718. 18 indexed citations
13.
Chen, Xisha, Kuan-Song Wang, Wei Guo, et al.. (2020). UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer. Theranostics. 10(4). 1833–1848. 37 indexed citations
14.
Yu, Pian, Xisha Chen, Min Tian, et al.. (2020). PKM2–c-Myc–Survivin Cascade Regulates the Cell Proliferation, Migration, and Tamoxifen Resistance in Breast Cancer. Frontiers in Pharmacology. 11. 550469–550469. 35 indexed citations
15.
Cao, Dongsheng, Shilong Jiang, Yidi Guan, et al.. (2020). A multi-scale systems pharmacology approach uncovers the anti-cancer molecular mechanism of Ixabepilone. European Journal of Medicinal Chemistry. 199. 112421–112421. 12 indexed citations
16.
Tian, Min, Xisha Chen, Lanya Li, et al.. (2020). Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis. Acta Pharmacologica Sinica. 42(7). 1180–1189. 35 indexed citations
17.
Yu, Pian, Haiyan Wang, Min Tian, et al.. (2019). Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro. Acta Pharmacologica Sinica. 40(9). 1237–1244. 106 indexed citations
18.
Jiang, Shilong, Yidi Guan, Xisha Chen, et al.. (2018). Tubeimoside-1, a triterpenoid saponin, induces cytoprotective autophagy in human breast cancer cells in vitro via Akt-mediated pathway. Acta Pharmacologica Sinica. 40(7). 919–928. 30 indexed citations
19.
Chen, Xisha, et al.. (2016). Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect. Acta Pharmacologica Sinica. 37(8). 1013–1019. 90 indexed citations
20.
Qiao, Aimin, Kuansong Wang, Yunsheng Yuan, et al.. (2016). Sirt3-mediated mitophagy protects tumor cells against apoptosis under hypoxia. Oncotarget. 7(28). 43390–43400. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026